Drug
Boceprevir clinical trials
Also written SCH 503034, Victrelis and MK-3034.
- studies test it
- 42
- open now
- 0
- in phase 3
- 16
- first study started
- 2005
How studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
42 studies that test it; most in 2011 (10)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 10 |
| 2012 | 10 |
| 2013 | 10 |
| 2014 | 3 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 9
- Phase 2
- 9
- Phase 3
- 16
- Phase 4
- 6
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 21
Merck Sharp & Dohme LLC (17) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Radboud University Medical Center (2) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Imperial College London (1) · GlaxoSmithKline (1) · Markus Peck-Radosavljevic (1) · Louis Stokes VA Medical Center (1)
Often tested with
Tested in the same studies.
Ribavirin (15) · Peginterferon alfa-2b (5) · Telaprevir (3) · Interferons (2) · Omeprazole (1) · Sildenafil (1) · Peginterferon alfa-2a (1) · Eltrombopag (1)
Studies
Open first, then newest update. How each study uses boceprevir is read from its arms, and is right about nine times in ten.
Testing it · 42
- Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver TransplantationCompletedPhase 2French National Agency for Research on AIDS and Viral HepatitisNCT01463956Written as Boceprevir
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /RibavirinTerminatedPhase 3Anna CrucetaNCT01718301Written as boceprevir
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV InfectionCompletedPhase 3National Institute of Allergy and Infectious Diseases (NIAID)NCT01482767Written as Boceprevir (BOC)
- Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)CompletedPhase 3Merck Sharp & Dohme LLCNCT00910624Written as Boceprevir
- The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)CompletedPhase 3Merck Sharp & Dohme LLCNCT01425203Written as Boceprevir
- Pharmacokinetic Study of the HCV Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor RaltegravirCompletedPhase 1Radboud University Medical CenterNCT01288417Written as boceprevir
- Pharmacokinetic Study of the HCV Protease Inhibitor Bo-cePRevir and the Proton Pump Inhibitor OMeprazOle (PROMO)CompletedPhase 1Radboud University Medical CenterNCT01470690Written as boceprevir
- The Boceprevir and Sildenafil Pharmacokinetics StudyCompletedPhase 1Imperial College LondonNCT01499498Written as Sildenafil and Boceprevir
- Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)CompletedPhase 3Merck Sharp & Dohme LLCNCT01390844Written as Boceprevir (BOC)
- Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)CompletedPhase 3Merck Sharp & Dohme LLCNCT01544920Written as Boceprevir
- Three-year Follow-up of Participants After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063)TerminatedPhase 2/3Merck Sharp & Dohme LLCNCT00689390Written as Boceprevir
- Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)TerminatedPhase 1Merck Sharp & Dohme LLCNCT01425190Written as Boceprevir
- A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)CompletedPhase 4Merck Sharp & Dohme LLCNCT01756079Written as boceprevir
- Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)CompletedPhase 3Merck Sharp & Dohme LLCNCT01945294Written as Boceprevir
- Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult SubjectsCompletedPhase 1GlaxoSmithKlineNCT01657552Written as Boceprevir
- Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05685AM2)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00845065Written as Boceprevir
- Comparison of Safety and Resulting Blood Level Profiles After Administration of a New Boceprevir Tablet Versus Its Current Capsule Formulation for Treatment of Chronic Hepatitis C (P06992)(COMPLETED)CompletedPhase 1Merck Sharp & Dohme LLCNCT01181804Written as boceprevir
- A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)CompletedPhase 2Merck Sharp & Dohme LLCNCT00959699Written as Boceprevir
- Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00708500Written as Boceprevir (SCH 503034)
- Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)CompletedPhase 3Merck Sharp & Dohme LLCNCT00705432Written as Boceprevir
See all 42 studies that test boceprevir →
Given in every arm · 5 — boceprevir is usual care beside what is tested
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)CompletedPhase 3Merck Sharp & Dohme LLCNCT01023035Written as Boceprevir
- Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P08034)WithdrawnPhase 3Merck Sharp & Dohme LLCNCT01590225Written as Boceprevir
- The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy VolunteersCompletedPhase 1Centre hospitalier de l'Université de Montréal (CHUM)NCT01627717Written as Maraviroc and boceprevir (14 days)
- A Study to Evaluate the Pharmacokinetic Effect of SCH 503034 (Boceprevir) on Methadone or Buprenorphine/Naloxone Plasma Concentrations (P08123)CompletedPhase 1Merck Sharp & Dohme LLCNCT01396005Written as boceprevir
- A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis CCompletedPhase 2Hoffmann-La RocheNCT01482403Written as boceprevir
As the comparator · 3 — what is tested is compared with boceprevir
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01353911Written as Boceprevir
- Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1TerminatedPhase 3Debiopharm International SANCT01446250Written as Boceprevir
- Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)WithdrawnPhase 3Merck Sharp & Dohme LLCNCT02204475Written as Boceprevir
Codes
What other systems call boceprevir · ClinicalTrials.gg INT004946
- MeSH (NLM) C512204N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamideConfirmed NLM, Wikidata
- UNII (FDA) 89BT58KELHBOCEPREVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1102129Confirmed FDA, Wikidata
- Wikidata Q410551boceprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C117292BoceprevirOne source FDA
- DrugBank DB08873One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C512204 | N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide | Confirmed NLM, Wikidata |
| UNII (FDA) | 89BT58KELH | BOCEPREVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1102129 | — | Confirmed FDA, Wikidata |
| Wikidata | Q410551 | boceprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C117292 | Boceprevir | One source FDA |
| DrugBank | DB08873 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.